![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: KRAS |
Gene summary for KRAS |
![]() |
Gene information | Species | Human | Gene symbol | KRAS | Gene ID | 3845 |
Gene name | KRAS proto-oncogene, GTPase | |
Gene Alias | 'C-K-RAS | |
Cytomap | 12p12.1 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A024RAV5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3845 | KRAS | LZE2T | Human | Esophagus | ESCC | 2.69e-07 | 1.22e+00 | 0.082 |
3845 | KRAS | LZE4T | Human | Esophagus | ESCC | 4.44e-17 | 4.47e-01 | 0.0811 |
3845 | KRAS | LZE5T | Human | Esophagus | ESCC | 3.77e-03 | 4.62e-01 | 0.0514 |
3845 | KRAS | LZE7T | Human | Esophagus | ESCC | 1.67e-10 | 6.29e-01 | 0.0667 |
3845 | KRAS | LZE8T | Human | Esophagus | ESCC | 1.07e-09 | 4.57e-01 | 0.067 |
3845 | KRAS | LZE20T | Human | Esophagus | ESCC | 1.03e-15 | 6.41e-01 | 0.0662 |
3845 | KRAS | LZE22D1 | Human | Esophagus | HGIN | 2.44e-05 | 2.48e-01 | 0.0595 |
3845 | KRAS | LZE22T | Human | Esophagus | ESCC | 7.96e-07 | 4.85e-01 | 0.068 |
3845 | KRAS | LZE24T | Human | Esophagus | ESCC | 4.79e-29 | 7.53e-01 | 0.0596 |
3845 | KRAS | LZE21T | Human | Esophagus | ESCC | 1.51e-08 | 8.13e-01 | 0.0655 |
3845 | KRAS | LZE6T | Human | Esophagus | ESCC | 1.79e-04 | 1.95e-01 | 0.0845 |
3845 | KRAS | P1T-E | Human | Esophagus | ESCC | 2.58e-13 | 8.44e-01 | 0.0875 |
3845 | KRAS | P2T-E | Human | Esophagus | ESCC | 1.19e-63 | 1.32e+00 | 0.1177 |
3845 | KRAS | P4T-E | Human | Esophagus | ESCC | 2.00e-68 | 1.45e+00 | 0.1323 |
3845 | KRAS | P5T-E | Human | Esophagus | ESCC | 4.25e-53 | 1.04e+00 | 0.1327 |
3845 | KRAS | P8T-E | Human | Esophagus | ESCC | 4.78e-58 | 1.39e+00 | 0.0889 |
3845 | KRAS | P9T-E | Human | Esophagus | ESCC | 1.35e-32 | 8.17e-01 | 0.1131 |
3845 | KRAS | P10T-E | Human | Esophagus | ESCC | 4.35e-62 | 1.33e+00 | 0.116 |
3845 | KRAS | P11T-E | Human | Esophagus | ESCC | 1.49e-15 | 6.91e-01 | 0.1426 |
3845 | KRAS | P12T-E | Human | Esophagus | ESCC | 7.90e-76 | 1.51e+00 | 0.1122 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003164727 | Esophagus | HGIN | regulation of protein stability | 96/2587 | 298/18723 | 2.21e-16 | 5.76e-14 | 96 |
GO:007099727 | Esophagus | HGIN | neuron death | 81/2587 | 361/18723 | 5.01e-06 | 1.61e-04 | 81 |
GO:004854527 | Esophagus | HGIN | response to steroid hormone | 73/2587 | 339/18723 | 6.06e-05 | 1.40e-03 | 73 |
GO:004873225 | Esophagus | HGIN | gland development | 88/2587 | 436/18723 | 1.34e-04 | 2.71e-03 | 88 |
GO:190121424 | Esophagus | HGIN | regulation of neuron death | 68/2587 | 319/18723 | 1.46e-04 | 2.91e-03 | 68 |
GO:006100820 | Esophagus | HGIN | hepaticobiliary system development | 37/2587 | 150/18723 | 2.58e-04 | 4.53e-03 | 37 |
GO:000188920 | Esophagus | HGIN | liver development | 36/2587 | 147/18723 | 3.61e-04 | 5.68e-03 | 36 |
GO:000931418 | Esophagus | HGIN | response to radiation | 88/2587 | 456/18723 | 6.26e-04 | 8.65e-03 | 88 |
GO:005140219 | Esophagus | HGIN | neuron apoptotic process | 52/2587 | 246/18723 | 1.01e-03 | 1.26e-02 | 52 |
GO:004887227 | Esophagus | HGIN | homeostasis of number of cells | 54/2587 | 272/18723 | 3.50e-03 | 3.23e-02 | 54 |
GO:190121510 | Esophagus | HGIN | negative regulation of neuron death | 43/2587 | 208/18723 | 4.04e-03 | 3.64e-02 | 43 |
GO:00094165 | Esophagus | HGIN | response to light stimulus | 61/2587 | 320/18723 | 5.20e-03 | 4.30e-02 | 61 |
GO:0031647111 | Esophagus | ESCC | regulation of protein stability | 223/8552 | 298/18723 | 5.76e-25 | 1.52e-22 | 223 |
GO:0048732111 | Esophagus | ESCC | gland development | 269/8552 | 436/18723 | 7.81e-12 | 2.95e-10 | 269 |
GO:007190016 | Esophagus | ESCC | regulation of protein serine/threonine kinase activity | 227/8552 | 359/18723 | 1.12e-11 | 4.10e-10 | 227 |
GO:000931419 | Esophagus | ESCC | response to radiation | 277/8552 | 456/18723 | 4.42e-11 | 1.43e-09 | 277 |
GO:0070997111 | Esophagus | ESCC | neuron death | 216/8552 | 361/18723 | 3.49e-08 | 6.45e-07 | 216 |
GO:0048545111 | Esophagus | ESCC | response to steroid hormone | 204/8552 | 339/18723 | 4.47e-08 | 8.11e-07 | 204 |
GO:000726510 | Esophagus | ESCC | Ras protein signal transduction | 201/8552 | 337/18723 | 1.44e-07 | 2.30e-06 | 201 |
GO:000756820 | Esophagus | ESCC | aging | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520839 | Esophagus | HGIN | Chemical carcinogenesis - reactive oxygen species | 92/1383 | 223/8465 | 2.41e-19 | 9.83e-18 | 7.80e-18 | 92 |
hsa0502230 | Esophagus | HGIN | Pathways of neurodegeneration - multiple diseases | 153/1383 | 476/8465 | 1.22e-18 | 4.41e-17 | 3.50e-17 | 153 |
hsa0501030 | Esophagus | HGIN | Alzheimer disease | 130/1383 | 384/8465 | 5.26e-18 | 1.71e-16 | 1.36e-16 | 130 |
hsa0471439 | Esophagus | HGIN | Thermogenesis | 91/1383 | 232/8465 | 1.97e-17 | 5.36e-16 | 4.25e-16 | 91 |
hsa0516730 | Esophagus | HGIN | Kaposi sarcoma-associated herpesvirus infection | 51/1383 | 194/8465 | 2.46e-04 | 2.69e-03 | 2.14e-03 | 51 |
hsa052039 | Esophagus | HGIN | Viral carcinogenesis | 53/1383 | 204/8465 | 2.58e-04 | 2.71e-03 | 2.15e-03 | 53 |
hsa0421828 | Esophagus | HGIN | Cellular senescence | 42/1383 | 156/8465 | 4.94e-04 | 5.03e-03 | 4.00e-03 | 42 |
hsa0413730 | Esophagus | HGIN | Mitophagy - animal | 23/1383 | 72/8465 | 7.69e-04 | 7.59e-03 | 6.03e-03 | 23 |
hsa0421020 | Esophagus | HGIN | Apoptosis | 36/1383 | 136/8465 | 1.67e-03 | 1.52e-02 | 1.20e-02 | 36 |
hsa0517029 | Esophagus | HGIN | Human immunodeficiency virus 1 infection | 51/1383 | 212/8465 | 2.16e-03 | 1.90e-02 | 1.51e-02 | 51 |
hsa0541739 | Esophagus | HGIN | Lipid and atherosclerosis | 51/1383 | 215/8465 | 2.95e-03 | 2.41e-02 | 1.91e-02 | 51 |
hsa0521620 | Esophagus | HGIN | Thyroid cancer | 13/1383 | 37/8465 | 4.20e-03 | 3.04e-02 | 2.41e-02 | 13 |
hsa0516639 | Esophagus | HGIN | Human T-cell leukemia virus 1 infection | 51/1383 | 222/8465 | 5.84e-03 | 4.05e-02 | 3.22e-02 | 51 |
hsa0516330 | Esophagus | HGIN | Human cytomegalovirus infection | 51/1383 | 225/8465 | 7.67e-03 | 4.63e-02 | 3.68e-02 | 51 |
hsa0520528 | Esophagus | HGIN | Proteoglycans in cancer | 47/1383 | 205/8465 | 8.23e-03 | 4.71e-02 | 3.74e-02 | 47 |
hsa05208115 | Esophagus | HGIN | Chemical carcinogenesis - reactive oxygen species | 92/1383 | 223/8465 | 2.41e-19 | 9.83e-18 | 7.80e-18 | 92 |
hsa05022113 | Esophagus | HGIN | Pathways of neurodegeneration - multiple diseases | 153/1383 | 476/8465 | 1.22e-18 | 4.41e-17 | 3.50e-17 | 153 |
hsa05010113 | Esophagus | HGIN | Alzheimer disease | 130/1383 | 384/8465 | 5.26e-18 | 1.71e-16 | 1.36e-16 | 130 |
hsa04714114 | Esophagus | HGIN | Thermogenesis | 91/1383 | 232/8465 | 1.97e-17 | 5.36e-16 | 4.25e-16 | 91 |
hsa05167114 | Esophagus | HGIN | Kaposi sarcoma-associated herpesvirus infection | 51/1383 | 194/8465 | 2.46e-04 | 2.69e-03 | 2.14e-03 | 51 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KRAS | SNV | Missense_Mutation | rs121913529 | c.35N>A | p.Gly12Asp | p.G12D | P01116 | protein_coding | deleterious(0) | benign(0.303) | TCGA-J2-A4AG-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KRAS | SNV | Missense_Mutation | rs121913529 | c.35G>T | p.Gly12Val | p.G12V | P01116 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-L9-A443-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KRAS | SNV | Missense_Mutation | rs121913529 | c.35N>A | p.Gly12Asp | p.G12D | P01116 | protein_coding | deleterious(0) | benign(0.303) | TCGA-MP-A4SY-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
KRAS | SNV | Missense_Mutation | rs121913529 | c.35N>T | p.Gly12Val | p.G12V | P01116 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-MP-A4T4-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KRAS | SNV | Missense_Mutation | rs121913529 | c.35G>T | p.Gly12Val | p.G12V | P01116 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-MP-A4T7-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
KRAS | SNV | Missense_Mutation | rs121913529 | c.35N>A | p.Gly12Asp | p.G12D | P01116 | protein_coding | deleterious(0) | benign(0.303) | TCGA-MP-A4T8-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | navelbine | SD |
KRAS | SNV | Missense_Mutation | rs121913529 | c.35N>T | p.Gly12Val | p.G12V | P01116 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-MP-A4TJ-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KRAS | SNV | Missense_Mutation | rs121913529 | c.35G>T | p.Gly12Val | p.G12V | P01116 | protein_coding | deleterious(0) | probably_damaging(0.972) | TCGA-MP-A4TK-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
KRAS | SNV | Missense_Mutation | rs121913529 | c.35G>A | p.Gly12Asp | p.G12D | P01116 | protein_coding | deleterious(0) | benign(0.303) | TCGA-NJ-A4YG-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
KRAS | SNV | Missense_Mutation | rs121913238 | c.181N>G | p.Gln61Glu | p.Q61E | P01116 | protein_coding | deleterious(0) | possibly_damaging(0.509) | TCGA-NJ-A4YP-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3845 | KRAS | CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME | lenalidomide | LENALIDOMIDE | 27458141 | |
3845 | KRAS | CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME | GA201 | IMGATUZUMAB | 23209031 | |
3845 | KRAS | CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME | 3144 | 28235199 | ||
3845 | KRAS | CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME | Cobimetinib | COBIMETINIB | ||
3845 | KRAS | CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME | BKM120 | BUPARLISIB | 26715098,22159814,26098748,24576621 | |
3845 | KRAS | CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME | AZD4785 | AZD-4785 | ||
3845 | KRAS | CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME | Gefitinib | GEFITINIB | 15696205,27338794,25870145 | |
3845 | KRAS | CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME | CGM097 | CGM-097 | 27659046 | |
3845 | KRAS | CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME | IRX4204 | |||
3845 | KRAS | CLINICALLY ACTIONABLE, DRUG RESISTANCE, ENZYME | MK2206 | MK-2206 | 26676756,25931518,26725216,22025163,27480147 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |